Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus chemoradiation in unresectable locally advanced ESCC
NCT05594914Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of the University of South China
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of the University of South China. Primary endpoints: Objective Response Rate at 24 months and Disease Control Rate at 24 months. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05594914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594914.